Cancer Family
Cutaneous Melanocytic Neoplasm
CI-CAN-00000154Explore in graph →
Non-malignant81 active trials1 approved drugs61 evidence items
- NCIt
- C7161
Loading cancer entity…
Cancer Family
CI-CAN-00000154Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07354152 | COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study(COPERGRAM1) | recruiting | — | 40 | Nantes University HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | terminated | N/A | 57 | University Hospital, BordeauxOTHER |
| 1 |
| Jun 23, 2026 |
| clinicaltrials |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | terminated | N/A | 1 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07628894 | Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy | not yet recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06319196 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma(ClearMe) | recruiting | Phase 2 | 54 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer | suspended | N/A | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT02965716 | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | active not recruiting | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | May 20, 2026 | clinicaltrials |
| NCT04253080 | Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors(ENZYMELA) | completed | N/A | 127 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04778449 | Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | recruiting | Phase 2 / Phase 3 | 135 | Linnaeus Therapeutics, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01955460 | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | terminated | N/A | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05628883 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03620019 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06008977 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy(EX-BOOST) | active not recruiting | N/A | 12 | AdventHealth Translational Research InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03276832 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06221397 | AI-based Medical Device Validation for Early Melanoma Detection(LEGIT_MC_EVCDA) | completed | — | 105 | AI Labs Group S.LINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06223659 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | recruiting | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02858869 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | completed | Phase 1 | 25 | Emory UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04020809 | Neoadjuvant Atezolizumab in Cutaneous Melanoma | active not recruiting | Phase 1 | 20 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03716193 | Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry | terminated | N/A | 3 | West Virginia UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06999980 | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)(Neo IRENIE) | recruiting | Phase 2 | 494 | Melanoma Institute AustraliaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | active not recruiting | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07376317 | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)(OTIMAS) | active not recruiting | Phase 2 | 29 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07307534 | Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study | not yet recruiting | N/A | 60 | Xijing HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03028948 | Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma | completed | N/A | 485 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | active not recruiting | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06994208 | Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.(MELA_2025) | recruiting | — | 25 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07251335 | Melanoma of the Skin and Exposure to Solar Ultraviolet Radiation at Work in Modena Territory: a Case-control Study to Promote an Active Search and Prevention of Occupational Diseases Based on Recent INAIL Criteria(Mesur) | recruiting | — | 300 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT01950390 | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 169 | National Cancer Institute (NCI)NIH | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05675709 | Enhancing Skin Cancer Early Detection and Treatment in Primary Care | completed | N/A | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06194929 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma(DETERMINE) | recruiting | Phase 1 / Phase 2 | 33 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | recruiting | Phase 2 | 99 | Emory UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT07148245 | Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma | recruiting | — | 300 | University of California, San FranciscoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04548817 | Neurocutaneous Melanocytosis Registry | recruiting | — | 100 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 24, 2026source: clinicaltrials